Evaluation of acupuncture for the treatment of pain associated with naturally-occurring osteoarthritis in dogs: a prospective, randomized, placebo-controlled, blinded clinical trial

Alice Baker-Meuten¹, Theresa Wendland¹, Shelly K. Shamir², Ann M. Hess³ and Felix Michael Duerr¹*

Abstract

Background: Acupuncture has been used as a treatment for pain associated with osteoarthritis (OA) for thousands of years; however, there is a lack of definitive evidence for this indication in humans or animals. The aim of this study was to prospectively evaluate the efficacy of acupuncture on lameness and clinical function in dogs affected by naturally-occurring OA using objective outcome measures. A total of 32 client-owned dogs completed this prospective, randomized, placebo-controlled, blinded clinical trial, using a cross-over design. Participants were assigned to receive placebo or acupuncture treatment once weekly for 4 weeks in random order with a two-week wash-out period in between treatment phases. Outcome measures included ground reaction forces (GRF), subjective orthopedic scoring (SOS), activity counts (AC), and owner-completed clinical metrology instruments (CMI; Canine Brief Pain Inventory [CBPI] and Client Specific Outcome Measures [CSOM]). For statistical comparison, baseline GRF, SOS, and CMI data were compared to data obtained 1 week after each treatment phase. Similarly, total weekly AC of the final week of each treatment phase were compared to the baseline week.

Results: Evidence of differences between baseline versus acupuncture and placebo treatments was not identified for the following outcome measures: GRF, AC, or SOS. However, evidence of differences was identified for some of the CMI scores, including the CSOM questionnaire which showed evidence of improvement when comparing baseline versus acupuncture (p = 0.0002) as well as between placebo versus acupuncture treatments (p = 0.035) but not between baseline versus placebo treatments (p = 0.221).

Conclusions: The applied acupuncture protocol did not show improvement in function when using objective outcome measures for OA in dogs; however, certain CMI measurements recorded some degree of treatment response.

Keywords: Osteoarthritis, Acupuncture, Canine, Electro-acupuncture, Accelerometers, Objective gait analysis
Background
Osteoarthritis (OA) affects humans and animals and is the most common joint disorder in the world [1]. Recent primary care data suggests that clinical OA is observed in approximately 5% of the canine population [2–4]. Furthermore, in an epidemiologic study investigating more than 12,000 German Shepherd Dogs in the UK, OA/musculoskeletal disease was the most common cause of euthanasia or natural death, surpassing even neoplasia [2].

Standard treatments for canine OA include non-steroidal anti-inflammatory drugs (NSAIDs), other oral pain medications, and nutraceuticals [5]. Non-steroidal anti-inflammatory drugs are considered the most effective oral pain medication available and are therefore widely used [6]. Unfortunately, some patients suffer from diseases that preclude the use of traditional NSAIDs and newer NSAIDs such as piprant drugs [7]. Furthermore, traditional NSAIDs have been associated with renal, gastrointestinal, and hepatic toxicity. Due to the fear of these side effects, some owners and veterinarians elect to pursue alternative or additional methods for treating OA, such as acupuncture [6–9].

Acupuncture originated as a part of traditional Chinese medicine and involves stimulation of specific points in the body (acupuncture points). There are many different methods of stimulating acupuncture points; however, acupuncture most commonly involves the placement of sterile needles into acupuncture points (i.e. defined by palpable anatomic locations) [8, 10]. Additional stimulation of the inserted needles, including applying an electrical current in case of electro-acupuncture (EA), have been used to increase the effect [8, 10–12]. The mechanism of action for acupuncture is complex, involving local mechanical effects, and the modulation of peripheral and central nervous system pain signaling pathways [8, 10]. For example, acupuncture has been shown to activate afferent nerve fibers (A-beta, A-delta, and C fibers) and regulate signaling molecules such as opioid peptides, glutamate, 5-hydroxytryptamine, and cholecystokinin to mitigate pain [10, 13, 14].

Available research investigating acupuncture for the alleviation of OA-associated pain does not draw firm conclusions regarding its efficacy in either veterinary or human medicine. Several studies have shown evidence of improvement in people receiving acupuncture; however, the benefits appear to be small and below the clinically relevant threshold [15, 16]. Acupuncture research in people is limited by an inability to perform effective blinding, since the treatment involves the physically noticeable aspect of inserting and manipulating the acupuncture needles [17]. Several studies have investigated the effectiveness of acupuncture for the treatment of canine OA [11, 18–22]. Some of these studies have utilized objective outcome measures; however, all authors acknowledged that further research is necessary. There has also been a systematic review in 2006 and a scoping review in 2017 on the efficacy of acupuncture in veterinary medicine, both of which concluded a need for more high-quality, randomized, controlled trials investigating the use of acupuncture in animals [11, 23].

The purpose of this study was to prospectively evaluate the efficacy of acupuncture to mitigate pain and improve function in dogs affected by naturally-occurring OA. The hypothesis was that acupuncture would result in decreased lameness and improved function when compared to placebo treatment.

Results
Seventy-two dogs were evaluated for enrollment, 36 dogs qualified and were enrolled in the study. There were 15 male castrated, 3 male intact, 17 female spayed, and 1 female intact dogs. The median age was 10 years (1.5–14 years). The range of enrollment weight was 9–47.5 kg (average 30.88 kg, SD ±8.7) and completion weight range was 9–48.4 kg (average 30.96, SD ±8.8), which was not significantly different (p = 0.668). There were 9 Labrador Retrievers, 4 Golden Retrievers, 2 German Shepherd Dogs, 1 Chesapeake Bay Retriever, 1 Newfoundland, 1 Siberian Husky, 1 West Highland Terrier, 1 English Springer Spaniel, 1 Entlebucher, and 15 mixed breed dogs. Thirty-two dogs had bilateral or multiple joint OA and 4 dogs had single joint OA with the following distribution of the primarily affected joint: elbow (n = 13), hip (n = 11), stifle (n = 8), tarsal (n = 2), and carpal (n = 2). See supplementary material for specifics on individual dogs.

Of the 36 patients enrolled in the clinical trial, four patients had incomplete or omitted data. One patient had completely omitted data due to not following the study protocol, one patient was removed from the study before the second phase (treatment) due to the development of inflammatory bowel disease necessitating treatment with immunosuppressive therapy, one patient had omitted data during the second phase (placebo) due to cervical disc disease causing forelimb lameness, and one dog would not tolerate the acupuncture protocol (despite the initial needle test at GV20 prior to enrollment) and was removed from the study during the second phase (treatment). Therefore, 32 dogs had complete data available for final analysis and 4 dogs had incomplete data consisting only of phase 1, which was included in the analysis. Four dogs were sensitive to needling (vocalizing, displaying anxiety about needle placement) but were able to complete their treatments without force or excessive restraint. The owner of one dog reported generalized soreness after his first acupuncture session, but not after subsequent sessions or during the placebo
phase. No adverse effects related to the acupuncture were observed or reported in any of the remaining dogs.

Evidence of differences was not identified for comparisons of baseline to the placebo and treatment phases or between placebo and treatment phases for any of the comparisons for the OGA, AC, or subjective orthopedic scores (SOS) data (Table 1). Based on Bonferroni adjusted F-tests (with \( p < 0.05 \)), evidence of differences was identified for several CMI comparisons. Specifically, client specific outcome measure (CSOM) data showed

| Table 1 Statistical Analysis Results: Comparison of baseline to treatment and placebo, and between treatment and placebo for all outcome measures |
|-------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                              | Baseline Mean (± SE) | Treatment Mean (± SE) | Tukey p-value between baseline and treatment | Tukey p-value between treatment and placebo | Bonferroni corrected F-test |
| %BWD                        | 20.5 (± 0.74) | Acupuncture 20.8 (± 0.87) | 0.73 | 0.96 | 0.58* |
|                             | Placebo 21.0 (± 0.83) | 0.55 | 1 |
| PVF                         | 40.3 (± 2.1) | Acupuncture 40.1 (± 2.7) | 0.97 | 0.99 | 1 |
|                             | Placebo 40.6 (± 2.4) | 0.94 | 1 |
| VI                          | 6.75 (± 0.41) | Acupuncture 6.53 (± 0.44) | 0.09 | 0.95 | 1 |
|                             | Placebo 6.55 (± 0.38) | 0.17 | 1 |
| ASI PVF Contralateral       | 16.4 (± 2.8) | Acupuncture 15.2 (± 2.8) | 0.31 | 0.96 | 1 |
|                             | Placebo 14.9 (± 3.0) | 0.46 | 1 |
| ASI PVF Ipsilateral         | 21.2 (± 1.9) | Acupuncture 22.4 (± 1.8) | 0.54 | 0.99 | 1 |
|                             | Placebo 21.8 (± 1.6) | 0.46 | 1 |
| ASI PVF Diagonal            | 22.0 (± 2.0) | Acupuncture 23.7 (± 1.8) | 0.35 | 0.94 | 1 |
|                             | Placebo 23.3 (± 1.3) | 0.19 | 1 |
| ASI VI Contralateral        | 16.0 (± 2.6) | Acupuncture 15.6 (± 2.9) | 0.84 | 0.97 | 1 |
|                             | Placebo 15.6 (± 2.6) | 0.94 | 1 |
| ASI VI Ipsilateral          | 27.2 (± 1.6) | Acupuncture 27.0 (± 2.0) | 0.92 | 0.93 | 1 |
|                             | Placebo 26.8 (± 1.7) | 0.10 | 1 |
| ASI VI Diagonal             | 26.9 (± 2.0) | Acupuncture 27.6 (± 2.0) | 0.80 | 0.95 | 1 |
|                             | Placebo 27.4 (± 1.9) | 0.61 | 1 |
| Total ACb                   | 1,065,154 (± 262,894) | Acupuncture 1,057,267 (± 241,479) | 0.31 | 0.84 | 1 |
|                             | Placebo 1,137,379 (± 351,793) | 0.67 | 1 |
| AC Sedentary                | 8083 (± 152) | Acupuncture 8051 (± 138) | 0.13 | 0.76 | 1 |
|                             | Placebo 8045 (± 165) | 0.47 | 1 |
| AC Light                    | 1250 (± 61) | Acupuncture 1246 (± 61) | 0.76 | 0.79 | 1 |
|                             | Placebo 1218 (± 70) | 0.10 | 1 |
| AC Moderate                 | 813 (± 98) | Acupuncture 760 (± 81) | 0.75 | 0.68 | 1 |
|                             | Placebo 775 (± 101) | 0.99 | 1 |
| SOS                         | 9.76 (± 0.53) | Acupuncture 9.27 (± 0.50) | 0.035* | 0.14 | 0.58 |
|                             | Placebo 9.76 (± 0.54) | 0.80 | 0.58 |
| CBPI PSS                    | 4.04 (± 0.29) | Acupuncture 3.34 (± 0.32) | 0.008* | 0.343 | 0.18 |
|                             | Placebo 3.60 (± 0.36) | 0.213 | 0.18 |
| CBPI PIS                    | 4.67 (± 0.36) | Acupuncture 3.50 (± 0.36) | 0.0001* | 0.257 | 0.003* |
|                             | Placebo 3.85 (± 0.42) | 0.018* | 0.003* |
| CSOM                        | 3.16 (± 0.11) | Acupuncture 2.66 (± 0.11) | 0.0002* | 0.035* | 0.005* |
|                             | Placebo 2.93 (± 0.13) | 0.221 | 0.005* |

*indicates evidence of a difference (based on \( p < 0.05 \); not considering Bonferroni adjustment)

*Bonferroni adjusted p-values are shown for all variables except BWD (primary response variable) where the raw unadjusted p-value is shown

bTotal AC was log10 transformed to satisfy model assumptions, but summary statistics are shown on original scale
evidence of a difference between baseline and treatment as well as between treatment and placebo (Table 1). There was also a significant difference observed between baseline and treatment for CBPI PSS and CBPI PIS data; however, significant differences were not observed for the comparison between treatment and placebo. For the latter, a statistically significant difference was also observed during the placebo phase and the differences observed here were confirmed with the Bonferroni adjusted F-test.

The questionnaire regarding owner assessment of treatment efficacy did not show evidence of a difference between treatment and placebo for behavior (median difference for acupuncture versus placebo is 0, Bonferroni adjusted Wilcoxon \( p = 0.51 \)) or clinical signs (median difference for acupuncture versus placebo is −1, Bonferroni adjusted Wilcoxon \( p = 0.15 \)). For the question regarding which phase of the study the owner thought their dog was receiving acupuncture, 58% \((n = 19)\) of owners guessed the phase correctly, 21% guessed incorrectly \((n = 7)\), 12% did not see a difference \((n = 4)\), and 9% were unsure \((n = 3)\).

**Discussion**

We rejected our hypothesis because we were unable to detect evidence of differences in the objective outcome measures OGA, SOS, and AC. However, some treatment response was found using owner completed CMI to assess clinical function and chronic pain. These results should be cautiously interpreted while considering the natural fluctuations in the disease process of OA as well as the caregiver placebo effect. Given that owners were blinded to the treatment allocation, our results are suggestive of a possible treatment effect of acupuncture in dogs with OA, which is consistent with previous canine studies and human data \([15, 16, 18, 19, 22]\). Several factors may explain the lack of evidence of differences for objective outcome measures including the true lack of a treatment effect of the utilized acupuncture protocol, variable responses of individuals to acupuncture, limitations of the utilized outcome measures to detect small differences in canines with OA, and the timing of outcome measurements.

Research investigating the effectiveness of acupuncture for treatment of OA in people has shown that the observed treatment benefits are small, therefore necessitating large sample sizes to detect differences. In canine OA research, most studies are designed to detect a difference similar to what is expected when treating patients with NSAIDs \([5, 7, 9]\). Furthermore, in many of these studies, patients do not receive additional treatments allowing to more clearly evaluate the treatment benefit. It may not be reasonable to expect acupuncture to exert a treatment effect of a similar magnitude to NSAID therapy; however, Teixeira, et al. found that owners perceived an improvement that lasted longer for acupuncture than NSAIDs \([22]\). In a clinical setting, acupuncture is most frequently employed as an additional strategy combined with many other conventional therapies; therefore, our study was designed to investigate the additive benefits of acupuncture and as such, most of the study participants were already on a regular medical management protocol that remained unchanged prior to and for the duration of the study period, often consisting of several treatments. While this approach is clinically relevant, it likely made it more difficult to detect evidence of differences between treatment groups.

People have been shown to have inherited genetic factors determining the density of cholecystokinin (CCK) receptors in their bodies and both the release of CCK and CCK receptor density are closely associated with an individual’s response to acupuncture \([13]\). It has also been demonstrated that there are differences in individual descending inhibitory pain controls and differences in processing physiologic pain and pathologic pain, which may contribute to the varying responses seen clinically and in randomized-controlled trials \([13]\). It has been proposed that this variability in individual responses to acupuncture due to physiologic mechanisms and genetic diversity amongst the population indicates that there are “responders” and “non-responders” to acupuncture analgesia \([13]\). It is possible that similar genetic diversity exists in dogs. The present study did not control for the possibility of responder versus non-responder patients since this phenomenon has not been objectively identified in dogs at this time.

In people, the interaction between the therapist and patient itself contributes to the observed placebo effects of sham acupuncture \([17]\). It is unclear how much of a role this interaction plays in dogs, but it can be theorized to be smaller since dogs are considered to be unaware of the treatment purpose. This, in combination with the inability to effectively blind people to acupuncture treatments, makes the canine an ideal translational model to investigate different acupuncture protocols. It is important to note that a substantial caregiver placebo effect has been described in dogs \([24]\), which could explain the evidence of differences identified for CBPI pain interference score (PIS) between baseline and treatment and between baseline and placebo, but not between the treatment and placebo treatments. In other words, since owners were blinded to when their dog was receiving acupuncture (and likely believed in acupuncture since enrolment in the study was voluntary), the positive effect during the placebo treatment is likely due to caregiver placebo effect. It should also be noted that these patients received similar attention from the staff involved in the study during their placebo phase which may have affected
their behavior; however, this was intentional to provide each dog with a similar hospital experience with the only variable being the acupuncture and acupuncturist.

Evaluation of at-home physical activity has been suggested as an important outcome measure for chronic diseases such as OA in people and dogs [25, 26]. The Actical accelerometer was used in this study since it has been previously validated as an outcome measure for physical activity monitoring in dogs [26–28]. An increase in 20% of weekly AC has been observed in dogs receiving NSAID therapy for OA compared with placebo [26]. While it has been described that the total amount of precipitation and daylight hours are unlikely to produce a clinically relevant change in activity data [29], that study did not evaluate other owner-induced factors that have been proposed to change daily AC such as availability to spend time with their dog and motivation to encourage activity [28]. We attempted to address some of the shortcomings of activity monitoring by measuring changes in the amount of sedentary time, light, moderate, and/or vigorous activity times [28]. However, we were unable to detect evidence of change in any of the activity categories in our population during either phase of the study. A recent report on functional linear modeling of activity data in dogs showed improvement in sleep in dogs with OA treated with meloxicam compared to placebo in a cross-over design study [30]. Their conclusions indicate that functional linear modeling is a more sensitive technique for analyzing activity data in dogs than traditional summary techniques. If further research suggests the validity of this technology it could be considered for future studies.

We chose %BWD as our primary outcome measure since it has been suggested to be the most accurate gait parameter when evaluating a heterogeneous group at a controlled velocity, and was associated with a lower variability than peak vertical force (PVF%) [31]. However, regardless of which OGA data point is utilized, ground reaction forces (GRF) only represent a short time point within the dog’s daily status and the data may be influenced by many variables (e.g. variability of OA-associated pain, level of prior activity etc.). Previous studies on acupuncture for OA in dogs also have not shown an improvement in OGA, yet have found differences in CMI scores [19, 22]. To date, there is a lack of objective outcome measures that reliably detect the clinical function of dogs in their natural environment over a longer time period. Until such outcome measures are available, CMIs are the most established method to assess this important feature of OA in canines. Future research is needed that allows for long-term measurement of kinetic parameters in the participant’s natural environment.

We chose to evaluate outcomes 1 week after the last acupuncture treatment. This decision was based on clinical relevance and previous research indicating that the peak benefits of acupuncture are observed after several once weekly treatments [18–22], and lasted up to 2 weeks following the final treatment in one study comparing NSAID therapy to acupuncture for hip OA [22]. Our results support those findings, since owners perceived an improvement 1 week after the final acupuncture treatment. Furthermore, similar to Teixeira et al. [22], we were unable to confirm this benefit with our primary outcome measure (OGA), it is therefore possible that the timing was past the maximum treatment effect. We may have observed greater differences if we would have implemented our time points closer to the last treatment. On the other hand, for a treatment to be clinically relevant for palliation of chronic disease, a shorter treatment effect may not be clinically meaningful.

In traditional Chinese medicine, acupuncture points are tailored to the patient’s pattern diagnosis and not necessarily to the Western diagnosis of OA. In practice, acupuncture protocols following Chinese or Western medicine techniques, are very dynamic and are frequently changed based on subjective assessment of how the patient responded to their previous treatment. This dynamism was confirmed in our survey. In our attempt to minimize confounding factors, we chose a set protocol based on treating the most severely or clinically affected joint. However, this approach does not necessarily represent the clinical treatment performed in daily practice. Similarly, some patients do not tolerate a large number of needles or EA, and the utilized protocol might have been too aggressive for some patients and not sufficient for others. Yet, EA is frequently used in OA research because it has been shown to alleviate inflammatory and neuropathic pain [12, 14].

The frequency of treatments also varies greatly between protocols. Available veterinary studies in dogs have reported five treatment sessions of dry-needle acupuncture in 1 month for hip OA [22], a single treatment of EA for elbow OA [19], once weekly treatments until improvement and then every other week for multiple neurologic and musculoskeletal diseases [21], and once weekly for at least three treatments or until satisfactory improvement for chronic OA [18]. Again, while it is possible that a greater treatment frequency may result in better results, this approach may not be clinically feasible given the cost and time requirements for performing acupuncture.

The majority of the patients in this study had OA in multiple limbs/joints, which makes it more challenging to identify changes in gait analysis parameters. Yet, this is the population frequently treated with acupuncture. Future studies may consider investigating single joint
OA; however, identification of a large enough sample size of single joint OA can be challenging.

Conclusions
In this study model, acupuncture did not improve weight-bearing on the primarily affected limb, increase activity as measured by accelerometry, or improve subjective orthopedic scores; however, an owner-perceived improvement in pain and function was identified.

Methods
This was a prospective, randomized, caregiver-blinded, placebo-controlled, cross-over design clinical trial. An a priori protocol was prepared and tested on pilot dogs prior to enrollment. This resulted in minor changes to the protocol. All enrolled cases followed the study protocol as described below.

Client-owned dogs with OA of the carpus, elbow, shoulder, tarsus, stifle, or hip joint of any breed or sex presenting to Colorado State University Veterinary Teaching Hospital were eligible for participation. The following inclusion criteria were used: body weight ≥ 10 kg, > 1 year of age, generally healthy on physical examination as well as unremarkable or stable and clinically insignificant changes on complete blood count and serum chemistry, a subjectively identifiable lameness (determined by a specialist in veterinary surgery and sports medicine; ≥2/5 but < 5/5 scores on a previously reported subjective lameness scale [28]) clearly attributable to a pelvic or thoracic limb lameness which can also be identified on OGA (values of the most affected limb had to be outside of normal range for %BWD of internal reference data), radiographically confirmed OA (greater than 6 months prior to enrollment), stable orthopedic disease (i.e. consistent lameness that has remained unchanged clinically for at least 4 weeks), a CBPI PSS and PIS ≥ 2 each [32], and willingness of the patient to tolerate the placement of one needle in GV-20 (to test for needle reactivity). If multiple limbs were affected, enrollment was based on the most severely affected limb/joint. To allow for placement of an accelerometer collar, dogs were also required to tolerate wearing a collar at all times. Dogs receiving medical management must have had a consistent OA management protocol for at least 4 weeks prior to inclusion into the study. Treatment protocols for management of OA were allowed to vary from patient to patient, but were to remain consistent throughout the study period: owners were asked to continue the current OA treatment protocol unless side effects were observed or clinical worsening required changes. Dogs were screened for study eligibility at their initial presentation, and if changes to their current treatment were suggested, all such treatments and medications were discussed with their owners. Owners were given the option to pursue the suggested changes, with re-evaluation performed a minimum of 4 weeks later to determine if the dog met the inclusion criteria.

Dogs with evidence of systemic disease (e.g. endocrinopathies), neoplasia, immune-mediated disease, lameness that was not attributable to radiographically confirmed OA, clinically significant orthopedic disease (other than OA), and evidence of neurologic disease based on a cursory neurologic examination were excluded. Animals with OA of the stifle joint due to chronic, stable cranial cruciate ligament disease were eligible; however, dogs with palpable stifle instability, lameness due to acute worsening of a suspected cranial cruciate ligament injury, or lameness due to recent meniscal injury were not eligible for enrollment. Dogs that underwent an orthopedic surgical procedure or any intra-articular injection within 6 months prior to evaluation were also ineligible for enrollment. If the owner was unable or unwilling to follow the proposed visit schedule, or fill out questionnaires, the dog was ineligible for enrollment.

Treatment groups
Each dog was randomly allocated into one of two groups (acupuncture during the first phase and placebo during the second phase [AP], or placebo during the first phase and acupuncture during the second phase [PA]) by drawing color-coded assignments to ensure allocation of equal numbers of animals per group. This was done after enrollment to ascertain allocation concealment. Baseline data were acquired for at least 3 weeks before initiation of treatment (starting with week 0). The placebo/treatment phases consisted of weekly visits for 4 weeks. One week after completion of the placebo/treatment phase, outcome data were collected to assess treatment efficacy of each respective phase. This resulted in a minimum of 2 weeks between the final placebo/treatment and the first placebo/treatment of the next phase (see the timeline in Fig. 1). Physical and orthopedic examinations were performed at each visit prior to treatment to evaluate for any change in clinical status. Caregivers were blinded to which group their dog was assigned. Staff that received or discharged the dogs, or performed and assisted in the examinations or acupuncture treatments were not blinded; however, the acupuncturist only had contact with the caregivers during the final baseline evaluation and at the time of study completion.

Acupuncture protocol
Prior to study initiation, a survey was conducted to poll veterinary acupuncturists about the most effective acupuncture treatment protocol for OA-associated pain. The purpose of this survey was to aid in the development of our acupuncture protocol that would
incorporate the points and procedures commonly used by veterinary acupuncturists from multiple training programs. This survey was sent to program directors of all United States veterinary acupuncture training programs to be distributed via email to their graduates. The survey was distributed to an unknown number of veterinary acupuncturists and was completed by 226 veterinarians (56% Chi Institute, 38% Curacore/Medical Acupuncture for Veterinarians, 6% International Veterinary Acupuncture Society) between 6/1/2016 and 8/24/2016. The survey consisted of 20 questions inquiring about demographics, protocols for treating arthritis, and specific acupuncture points used to treat OA patients. Questions were comprised of a combination of multiple choice and open-ended questions where additional points could be listed and commentary could be made by survey responders. For example, when practitioners were asked to list specific points for treatment of an affected joint, choices of regional points were provided by multiple choice answer in addition to a comment box where points could be manually entered. Practitioners were asked to list points by their common alphanumeric codes for ease of analysis. Points were tallied by combining multiple choice data and word recognition counts verified by manual counts of the entries in the comment boxes. When Chinese names were provided instead of alpha-numeric codes, these were manually converted when possible to their alpha-numeric codes or tallied manually when names were unique. The treatment protocol utilized for this project (Table 2) was based on a combination of these survey results (Table 3) and protocols recommend in the published literature [18, 19, 22, 34].

Acupuncture treatments were performed by a single certified veterinary acupuncturist once weekly for 4 weeks during the treatment phase of the study using commercially available acupuncture needles (Hwato needles, Suzhou, China; uncoated, size 0.25x30mm, 0.22x30mm, and 0.22 x 15 mm). The number of needles placed per treatment varied between 20 and 30 needles per animal depending on the protocol for the affected joint (Table 2). Needles were stimulated by rotating in a clockwise and counter-clockwise motion as the needle was advanced to attempt to achieve needle grasp (also known as “De Qi” in Chinese medicine). Duration of needle placement was between 15 and 20 min. Leads from an electro-stimulator (JM-2A Electro-acupuncture, Wuxi Jiajian Medical Instrument, Inc., Wuxi, China) were connected (according to
Table 2  Acupuncture points used in the present study based on the affected joint(s)

| Affected Joint | Acupuncture points in all dogs (placed bilaterally if paired) | Points for all pelvic/thoracic limb OA (placed bilaterally) | Electro-acupuncture over the primarily affected joint (unilateral EA) | Additional points used for each primarily affected joint (bilaterally placed) |
|----------------|---------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
| Hip            | GV-20<sup>a</sup> BL-11—BL-23 GB-29—GB-30                    | BL-40, ST-36, BL-54, BL-60, KID-3, LIV-3                   | GB-29—GB-30                                                        | Jian jiao, GB-41                                                     |
| Stifle         | GB-14<sup>a</sup>—Bai hui<sup>a</sup>                        | BL-60—LIV-3                                                | SP-10—GB-34                                                        | SP-9, GB-33, KID-3                                                  |
| Tarsus         |                                                              | BL-13, GB-21, LI-4, SI-9, BL-10                            | TH-14—LU-1                                                         | LI-15, SI-3, TH-3                                                  |
| Shoulder       |                                                              | LI-11—LU-5                                                |                                                                    |                                                                    |
| Elbow          |                                                              | PC-6—LI-4                                                 |                                                                    |                                                                    |
| Carpus         |                                                              |                                                            |                                                                    |                                                                    |

All dogs were treated first with GV-20. The remaining points were not placed in any specific order; electro-acupuncture leads were connected between the two points (indicated by “—”) after all of the needles had been placed. Based on myofascial palpation of individual patients, 0–3 additional points not included in this table were allowed to be placed.

— electro-acupuncture lead connections between these points. *non-paired points

Alpha-numeric acupuncture point abbreviations [33]: GV Governing Vessel, BL Bladder, ST Stomach, KID Kidney, LIV Liver, GB Gall Bladder, L Large Intestine, SI Small Intestine, SP Spleen, TH Triple Heater, LU Lung, PC Pericardium, # is the location on the meridian/channel

Table 3  Survey of veterinary acupuncturists

| Abbreviated Survey Question | Survey Responses |
|-----------------------------|------------------|
| Which is more effective at treating OA: EA, manual acupuncture, or combination? | 72% combination, 21% manual acupuncture alone, 7% EA alone |
| Do you generally use the same regional points around an affected joint, or does it vary depending on the patient? | 89% variable, 7% same |
| With OA of a single joint, how many individualized regional points do you use on average in addition to “usual points”? | 45% 1–3 additional, 32% 4–6 additional |
| With OA of a single joint, do you typically only acupuncture the affected limb (unilateral), or also treat the opposite limb (bilateral)? | 64% treat bilaterally, 15% treat only the affected limb |
| With OA of a single joint, do you typically treat for compensatory pain distant from source of lameness in addition to the primary source of the lameness? | 99% yes, 1% no |
| List the most common points you use to treat for compensatory pain based on thoracic or pelvic limb lameness. | 10 most frequently mentioned for the thoracic limb: GV-14, BL-11, BL-13, GB-21, LI-4, SI-9, BL-10, LI-10, LI-11, LIV-3 |
| What regional points do you most commonly use for specific joints of the thoracic limb? | Shoulder: SI-9 (71%), GB-21 (67%), BL-11 (57%), TH-14 (63%), LI-15 (61%), and BL-10 (24%). |
| What regional points do you most commonly use for specific joints of the pelvic limb? | Elbow: LI-11 (75%), LI-10 (62%), LU-5 (43%), SI-9 (40%), TH-10 (38%). |
| Carpus: PC-6 (61%), HT-7 (56%), LI-4 (61%), LU-7 (38%), SI-3 (32%), and TH-5 (26%). |
| Ranking of most to least ‘responsive to acupuncture’ arthritic joint in the appendicular skeleton. | 1. Hip, 2. Stifle, 3. Shoulder, 4. Elbow, 5. Tarsus, 6. Carpus |
| Which points do you recommend using for every patient with OA? | Bai hui (67%), GV-20 (38%), ST-36 (51%), BL-11 (26%), BL-23 (40%), LIV-3 (23%). |
Table 2) after all needles were placed. The points were stimulated continuously at 2 Hz for 5–10 min, followed by alternating wave pulses at 80 and 120 Hz for 5–10 min. An attempt was made to replace needles if they fell out prior to the first 10 min after needle placement. Animals were monitored for adverse effects and the treatment was terminated if the patient was showing any signs of discomfort as judged by the acupuncturist based on clinical experience.

**Placebo protocol**
The duration of the placebo treatment visits (time away from the owner) was the same amount of time as the acupuncture treatment visits. No sham acupuncture (i.e. insertion of needles into non-acupuncture points) treatment was performed; however, the patient was kept in the same room where the acupuncture was performed, unkenneled and with a staff member that also assisted in the acupuncture treatments, for the same period of time it would take to perform the acupuncture. The acupuncturist did not have contact with the patients during the placebo phase of the study and to ascertain owner blinding, patients were always received by a staff member other than the acupuncturist.

**Outcome measurements**

**Objective gait analysis**
Objective gait analysis using a pressure sensitive walkway (Tekscan HRV Walkway 6 VersaTek system, Tekscan Inc., South Boston, MA) analysis system were collected at week 0 for enrollment, week 1 for acclimation, week 2 for baseline, week 7 for the end of the first placebo/treatment phase of the study, and week 12 for the end of the second placebo/treatment phase of the study (see Fig. 1). OGA data were collected using a previously described protocol [28]. The following parameters were calculated and averaged from six valid trials of each OGA measurement for the most affected limb: PVF and vertical impulse (VI) normalized by body weight (PVF%, VI%), %BWD, and asymmetry indices (ASI) as previously described [35]. These were calculated using the following formulas:

\[
\text{PVF}\% = \frac{\text{PVF} [\text{N}] / (\text{BW} [\text{kg}] \times 9.8066)}{100}
\]

\[
\text{VI}\% = \frac{\text{VI} [\text{N} \times \text{sec}] / (\text{BW} [\text{kg}] \times 9.8066)}{100}
\]

\[
\%\text{BWD} = \left( \frac{\text{PVF} [\text{N}] \text{ of the limb/total PVF} [\text{N}]}{\text{all four limbs in one gait cycle}} \right) \times 100
\]

\[
\text{ASI} (\%) = \left( \text{FL} - \text{HL} / \text{FL} + \text{HL} \right) \times 100
\]

**Accelerometry**
Total AC were measured via accelerometry (Actical, Murrysville, PA, USA). The accelerometer was attached to an individual collar (in addition to the dog’s regular collar) after removing the metal ring on the collar used for leash attachment and securing the accelerometer with two zip ties. Data were recorded continuously throughout the study period. The epoch, or window length of measurement by the device, was set to 60 s. Only AC data with a minimum of 140 min of recorded activity per day were used for analysis [28]. Automatically generated data from each patient’s accelerometer was recorded as the number of minutes per week spent in different activity intensities (sedentary, light, moderate, and vigorous) [28]. Vigorous activity was not included in the statistical analysis due to the majority of patients having spent zero time in this category.

**Subjective Orthopedic Score (SOS)**
A specifically developed orthopedic scoring system (Additional file 1) was used to quantify veterinary exam findings. The SOS was modified based on previous subjective scoring systems [7, 36–40]. It consists of 6 components and each component is rated on a scale of 0–4 (with 0 = normal and 4 = severe impairment) resulting in a total score of 0–24 (with 24 being the worst). The SOS was performed by the same observer for each patient at each time point (to avoid inconsistencies in between observers assigning the scores). An attempt was made to blind the observer, however, due to the clinical proximity of this observer to the acupuncturist, this was not accomplished in several cases. As such, this study was not considered double-blinded.

**Owner-completed questionnaires**
The CBPI and CSOM questionnaires were filled out by the same owner in a dependent fashion on week 0 for enrollment, week 2 for baseline, week 7 for the end of the first placebo/treatment phase of the study, and week 12 for the end of the second placebo/treatment phase of the study (see Fig. 1). CBPI questionnaires were conducted as described previously [32]. CSOM questions based on previously published information were divided into activity and behavior categories [41]. Owners were asked to pick five time and place specific questions related to activity and grade them on a 1–5 scale (1 = no problem, 2 = a little problematic, 3 = quite problematic, 4 = severely problematic, and 5 = impossible) and three questions related to behavior also graded on a 1–5 scale (1 = significantly less than normal, 2 = less than normal, 3 = normal amount, 4 = more than normal, and 5 = significantly more than normal). These questions were normalized for analysis with higher numbers indicating worsening of symptoms and lower numbers indicating improvement of symptoms.

Additionally, owners were asked to complete a treatment efficacy form (Additional file 2) at week 7 and
week 12 to record their impression of whether clinical signs and behavior changed (improved, stayed the same, worsened, or unsure of change) following each phase of the study. A final question was asked at the end of the study to assess which treatment group they felt their dog had been allocated to (assuming that the treatment would be beneficial) and whether or not the owner thought the dog improved at all during the study.

**Statistical analysis**

Open-source software (http://hedwig.mgh.harvard.edu/sample_size/js/js_crossover_quant.html) was used to calculate the sample size using baseline data from two pilot dogs that were not included in the data analysis. To detect a 5% change in %BWD (significance level: 0.05; within patient standard deviation: 1.14; power: 0.9; minimal detectable difference in means: 1.25), 20 patients would have to be enrolled. To account for attrition and since this cross-over design has not been extensively used in canine OA research, we enrolled 36 dogs. Analysis was performed using SAS v9.4 (SAS Institute Inc., Cary, NC). Residual diagnostic plots were used to evaluate model assumptions (normality and equal variance). Objective gait analysis (%BWD, PVF%, VI%, and ASI [PVF contralateral, PVF ipsilateral, VI contralateral, VI ipsilateral, VI diagonal], AC (Total AC, sedentary, light, and moderate), SOS, and CMI (CBPI, and CSOM) were analyzed using a mixed model that was fit separately for each response variable at baseline, post-acupuncture, and post-placebo (treating visit as a fixed effect). Each individual dog was included as a random effect to account for repeated measures. Tukey adjusted pairwise comparisons were used to compare between visits. With the exception of the primary outcome (%BWD), Bonferroni adjusted F-tests were used to account for multiple testing of the other variables. The Wilcoxon signed rank test was used to evaluate the treatment efficacy questionnaire since this data was not normally distributed. Bonferroni adjusted pairwise comparisons are also presented for the questionnaire data. A paired t-test was used to compare enrollment versus completion weights.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12917-020-02567-1.

**Additional file 1.** Subjective Orthopedic Score (SOS).

**Additional file 2.** Owner assessment of treatment efficacy.

**Additional file 3.** Individual dog table.

**Abbreviations**

%BWD: % body weight distribution; AC: Activity count; AP: Acupuncture followed by placebo; ASI: Asymmetry index; CBPI: Canine brief pain inventory; CCK: Cholecystokinin; CMI: Clinical metrology instruments; CSOM: Client specific outcome measures; EA: Electro-acupuncture; GRF: Ground reaction forces; NSAIDs: Non-steroidal anti-inflammatory drugs; OA: Osteoarthritis; OGA: Objective gait analysis; PA: Placebo followed by acupuncture; PIS: Pain interference score; PSS: Pain severity score; PVF: Peak vertical force (% normalized to body weight); SOS: Subjective orthopedic score; VI: Vertical impulse (% normalized to body weight).

**Acknowledgements**

We would like to thank the Eldred Foundation for making this study possible.

**Authors’ contributions**

All authors have read and approved the final manuscript. ABM: study design, administered acupuncture treatments, data interpretation, and manuscript drafting. TW: design and conduction of survey, study conception and design, manuscript revising. SKS: patient evaluation and enrollment, data collection and organization, manuscript revising. AH: analysis, manuscript revising. FD: study conception, design, organization, data collection, analysis and interpretation, and manuscript drafting.

**Funding**

This study was funded by the Eldred Foundation, Austin, TX. The Eldred Foundation did not play any role in the design, execution, analysis, or reporting of this study.

**Availability of data and materials**

The datasets used and analyzed during this study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

This study was approved by the Clinical Research Review Board at Colorado State University Veterinary Teaching Hospital (VCS#2015–031) and written consent was obtained from dog owners prior to enrollment.

**Consent for publication**

Not Applicable.

**Competing interests**

None.

**Author details**

1Colorado State University Veterinary Teaching Hospital, 300 W Drake Rd, Fort Collins, CO 80523, USA. 2University of Minnesota Veterinary Medical Center, 1365 Gortner Ave, St Paul, MN 55108, USA. 3Department of Statistics, Colorado State University, 300 W Drake Rd, Fort Collins, CO 80523, USA.

Received: 10 April 2020 Accepted: 11 September 2020

**Published online:** 25 September 2020

**References**

1. Arden N, Nevitt MC. Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol. 2006;20:3–25.
2. O’Neill DG, Coulson NR, Church DB, et al. Demography and disorders of German shepherd dogs under primary veterinary care in the UK. Canine Genet Epidemiol. 2017;4:7.
3. Anderson KL, O’Neill DG, Brodbelt DC, et al. Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Sci Rep. 2018;8:5641.
4. Banfield Banfield Pet Hospital Veterinary Emerging Topics (Vet) Report, in, Vol. https://www.banfield.com/exchange/latest-thinking/vet-report/overview, 2019.
5. Rychel JK. Diagnosis and treatment of osteoarthritis. Top Companion Anim Med. 2010;25:20–5.
6. Monteiro-Steagall BP, Steagall PVM, Lascelles BDQ. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med. 2013;27:1011–9.
7. Rausch-Derra L, Huebner M, Wofford J, et al. A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. J Vet Intern Med. 2016;30:756–63.
8. Fry LM, Neary SM, Sharrock J, et al. Acupuncture for analgesia in veterinary medicine. Top Companion Anim Med. 2014;29:35–42.

9. Belshaw Z, Asher L, Dean RS. The attitudes of owners and veterinary professionals in the United Kingdom to the risk of adverse events associated with using non-steroidal anti-inflammatory drugs (NSAIDs) to treat dogs with osteoarthritis. Prev Vet Med. 2016;131:121–6.

10. Wright BD. Acupuncture for the treatment of animal pain. Vet Clin. 2019;49:1029–39.

11. Rose WJ, Sargeant JM, Hanna WB, et al. A scoping review of the evidence for efficacy of acupuncture in companion animals. Anim Health Res Rev. 2017;18:177–85.

12. Chomshimwat P, Ma A. Comparison of the effects of electro-acupuncture and laser acupuncture on pain relief and joint range of motion in dogs with coxofemoral degenerative joint disease. Am J Tradit Chin Vet Med. 2019;14.

13. Zhao Z-Q. Neural mechanism underlying acupuncture analgesia. Prog Neurobiol. 2008;83:355–75.

14. Zhang R, Lao L, Ren K, et al. Mechanisms of acupuncture–electroacupuncture on persistent pain. Anesthesiology. 2014;120:482–503.

15. Manheiner E, Cheng K, Linde K, et al. Acupuncture for peripheral joint osteoarthritis. Cochrane Database Syst Rev. 2010, Issue 1. Art. No.: CD001977.

16. Seca S, Miranda D, Cardoso D, et al. Effectiveness of acupuncture on pain, physical function and health-related quality of life in patients with rheumatoid arthritis: a systematic review of quantitative evidence. Chin J Integr Med. 2019;25:704–9.

17. Chen H, Yang M, Ning Z, et al. A guideline for randomized controlled trials of acupuncture. Am J Chin Med. 2019;47:1–18.

18. Janssens LAA. Observations on acupuncture therapy of chronic osteoarthritis in dogs: a review of sixty-one cases. J Small Anim Pract. 1986;27:825–37.

19. Kapatkin AS, Tomasic M, Beech J, et al. Effects of electrostimulated acupuncture on ground reaction force and pain scores in dogs with chronic elbow joint arthritis. J Am Vet Med Assoc. 2006;228:1350–4.

20. Lane DM, Hill SA. Effectiveness of combined acupuncture and manual therapy relative to no treatment for canine musculoskeletal pain. Can Vet J. 2016;57:407–14.

21. Silva NEOF, Luna SPL, Joaquim JGF, et al. Effect of acupuncture on pain and quality of life in canine neurological and musculoskeletal diseases. Can Vet J. 2017;58:941–51.

22. Teixeira LR, Luna SP, Matsubara LM, et al. Owner assessment of chronic pain intensity and results of gait analysis of dogs with hip dysplasia treated with acupuncture. J Am Vet Med Assoc. 2016;249:1031–9.

23. Habacher G, Pittler MH, Ernst E. Effectiveness of acupuncture in veterinary medicine: systematic review. J Vet Intern Med. 2006;20:480–8.

24. Conzemius MG, Evans RB. Caregiver placebo effect for dogs with lameness from osteoarthritis. J Am Vet Med Assoc. 2012;241:1314–9.

25. Hansen BD, Lascelles BDX, Keene BW, et al. Evaluation of an accelerometer for at-home monitoring of spontaneous activity in dogs. Am J Vet Res. 2007;68:468–75.

26. Brown DC, Boston RC, Farrar JT. Use of an activity monitor to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. 2010;237:665–70.

27. Morrison R, Reilly J, Penpraze V, et al. A 6-month observational study of changes in objectively measured physical activity during weight loss in dogs. J Small Anim Pract. 2014;55:566–70.

28. Mejia S, Duer F, Salmon M. Comparison of activity levels derived from two accelerometers in dogs with osteoarthritis: Implications for clinical trials. Vet J (London, England: 1997). 2019;252:105355.

29. Katz EM, Scott RM, Thomson CB, et al. Evaluation of the environmental bias on accelerometer-measured total daily activity counts and owner survey responses in dogs with osteoarthritis. Vet Comp Orthop Traumatol. 2017;30:385–90.

30. Gruen M, Samson D, Lascelles B. Functional linear modeling of activity data shows analgesic-mediated improved sleep in dogs with spontaneous osteoarthritis pain. Sci Rep. 2019;9:1–6.

31. Kano WT, Rahal SC, Agostinho FS, et al. Kinetic and temporospatial gait parameters in a heterogeneous group of dogs. BMC Vet Res. 2016;12:2.

32. Brown DC, Bell M, Rhodes L. Power of treatment success definitions when the canine brief pain inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis. Am J Vet Res. 2013;74:1467–73.

33. Xie H, Preast V, Xie’s veterinary acupuncture. Ames: Blackwell Publishing; 2007.

34. Shmalberg J, Burgess J, Davies W. A randomized controlled blinded clinical trial of electro-acupuncture administered one month after cranial cruciate ligament repair in dogs. Am J Tradit Chin Vet Med. 2014;9.

35. Oosterlinck M, Bosmani T, Gastlys F, et al. Accuracy of pressure plate kinetic asymmetry indices and their correlation with visual gait assessment scores in lame and nonlame dogs. Am J Vet Res. 2011;72:820–5.

36. Black LL, Gaynor J, Gahring D, et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter controlled trial. Vet Ther. 2007;8:272.

37. Harman R, Carlson K, Gaynor J, et al. A prospective, randomized, masked, and placebo-controlled efficacy study of intrarticular allogenic adipose stem cells for the treatment of osteoarthritis in dogs. Front Vet Sci. 2016;3:81.

38. Bubenlik L, Johnson SA, Smith MM, et al. Evaluation of lameness associated with arthroscopy and arthrotomy of the normal canine cubital joint. Vet Surg. 2002;31:23–31.

39. Vaseur P, Johnson A, Budsberg S, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc. 1995;206:807–11.

40. Tomas A, Bledsoe D, Wall S, et al. Initial evaluation of a canine stiffe arthroscopy post-operative pain model. Vet J. 2015;204:293–8.

41. Olsen A, Johnson V, Webb T, et al. Evaluation of intravenously delivered allogeneic mesenchymal stem cells for treatment of elbow osteoarthritis in dogs: a pilot study. Vet Comp Orthop Traumatol. 2019;32:173–81.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.